Monopar Therapeutics Inc (NASDAQ: MNPR) completed a pre-specified interim analysis for its Validive Phase 2b/3 VOICE trial for the prevention of severe oral mucositis (SOM) in patients undergoing chemoradiotherapy for oropharyngeal cancer (OPC).
NetEase Inc (NASDAQ: NTES) lost about $7 billion from its market value this week, driven by concerns over competition from Tencent Holdings Ltd's (OTC: TCEHY) upcoming party game, Dream Star.